Biotech pharma

Sequence Bio

Website
Founded 2013Origin source ↗Checked 2026-09-15

Overview

90% of drug candidates fail, delaying help for those in need. We’re on a mission to change that. Better drug target discovery powered by the Newfoundland founder effect.

Company description As recorded 2026-11-08
LinkedIn GitHub About
Biotech pharmaAnalyticsBusinessesEnterpriseLicensing

Founders & team

Jeremy Grushcow

Founder

Ph.D. in Molecular Genetics and Cell Biology (University of Chicago, 2000); J.D. with Honors (University of Chicago Law School, 2003). Previously: CBO, Sequence Bio S19 (Raised >$10m; LOIs signed with Sema4, Helix and Biogen); EVP, Strategic Development, Antibe Therapeutics (International partnerships, public company financings and disclosures; preclinical through Phase 1 for a novel pain therapeutic) Best dog dad ever; 7 out of 10 human dad.

LinkedIn X
Founder profile As recorded 2026-09-15
52team members reported
Source-reported As recorded 2026-09-15

Founded 2013 · Source

News & product activity

Sources & observations

Y Combinator

Profile depthverified profile
Website observationwebsite reachable
Last website check2026-11-11
Location · source statedSt. John's, NL, Canada
Pricing evidenceNo pricing page confirmed
Maturity: Not assessed · 3 of 6 areas documented

Source-based assessment · automated evidence rules

The retained text does not establish product availability or customer use.

Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.

Stage definitions
independent websitesource corroborationreachable websitedescriptive evidenceclassified market and modelsourced peoplesourced founding year
startup.observe Directory coverage · Sources & method